The European Society for Medical Oncology (ESMO) Congress 2025 brought leading oncology experts from around the world together to share the latest advances, emerging trends, and innovative approaches shaping cancer care across multiple disease types and clinical settings. The event provided a unique opportunity for knowledge exchange, collaboration, and discussion of evolving best practices in oncology. Fast Five highlights key insights captured live from the Congress, providing concise and practical takeaways for clinicians, researchers, and healthcare professionals.
In this episode, Barbara Schmalfeldt, University Medical Center Hamburg-Eppendorf, Germany, highlights the major updates in gynaecological cancers presented at ESMO 2025.
- The KEYNOTE-B96 trial and its impact on platinum-resistant ovarian cancer treatment
- Emerging immunotherapy shaping recurrent ovarian cancer management
- Progress and challenges in overcoming gynaecological cancer resistance
- Early data and discussion from the REJOICE-Ovarian01 trial
Stay tuned for more in-depth coverage of the ESMO Congress in the upcoming EMJ Oncology Journal, publishing on 2nd December 2025.
